StockData
Keros Therapeutics, Inc. logo

Keros Therapeutics, Inc. (KROS) stock

KROSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$11.31+1.28 (+12.76%)

Close on Nov 17, 2026Market cap $224.25MP/E –Yield –

Keros Therapeutics enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Keros Therapeutics's enterprise value was -$68.45M on Nov 11, 2026, against $16.78M a year earlier. Over the last 5 years it ranged from -$179.04M to $1.82B, with a median of $648.45M.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026-$68.45M-151.2%
2025Dec 31, 2025$133.80M+47.4%
2024Dec 31, 2024$90.78M-89.8%
2023Dec 29, 2023$892.15M-11.9%
2022Dec 30, 2022$1.01B-11.7%
2021Dec 31, 2021$1.15B-11.0%
2020Dec 31, 2020$1.29B–

More Keros Therapeutics figures

See a number that looks wrong?